These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 31499384)

  • 1. The clinical role of VeriStrat testing in patients with advanced non-small cell lung cancer considered unfit for first-line platinum-based chemotherapy.
    Lee SM; Upadhyay S; Lewanski C; Falk S; Skailes G; Woll PJ; Hatton M; Lal R; Jones R; Toy E; Rudd R; Ngai Y; Edwards A; Hackshaw A
    Eur J Cancer; 2019 Oct; 120():86-96. PubMed ID: 31499384
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Retrospective Assessment of a Serum Proteomic Test in a Phase III Study Comparing Erlotinib plus Placebo with Erlotinib plus Tivantinib (MARQUEE) in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer.
    Buttigliero C; Shepherd FA; Barlesi F; Schwartz B; Orlov S; Favaretto AG; Santoro A; Hirsh V; Ramlau R; Blackler AR; Roder J; Spigel D; Novello S; Akerley W; Scagliotti GV
    Oncologist; 2019 Jun; 24(6):e251-e259. PubMed ID: 30139835
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The serum-based VeriStrat® test is associated with proinflammatory reactants and clinical outcome in non-small cell lung cancer patients.
    Fidler MJ; Fhied CL; Roder J; Basu S; Sayidine S; Fughhi I; Pool M; Batus M; Bonomi P; Borgia JA
    BMC Cancer; 2018 Mar; 18(1):310. PubMed ID: 29558888
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized Phase III Trial of Erlotinib versus Docetaxel in Patients with Advanced Squamous Cell Non-Small Cell Lung Cancer Failing First-Line Platinum-Based Doublet Chemotherapy Stratified by VeriStrat Good versus VeriStrat Poor. The European Thoracic Oncology Platform (ETOP) EMPHASIS-lung Trial.
    Peters S; Stahel RA; Dafni U; Ponce Aix S; Massutí B; Gautschi O; Coate L; López Martín A; van Heemst R; Berghmans T; Meldgaard P; Cobo Dols M; Garde Noguera J; Curioni-Fontecedro A; Rauch D; Mark MT; Cuffe S; Biesma B; van Henten AMJ; Juan Vidal Ó; Palmero Sanchez R; Villa Guzmán JC; Collado Martin R; Peralta S; Insa A; Summers Y; Láng I; Horgan A; Ciardiello F; de Hosson S; Pieterman R; Groen HJM; van den Berg PM; Zielinski CC; Chittazhathu Kurian Kuruvilla Y; Gasca-Ruchti A; Kassapian M; Novello S; Torri V; Tsourti Z; Gregorc V; Smit EF;
    J Thorac Oncol; 2017 Apr; 12(4):752-762. PubMed ID: 28017787
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic Value of Serum Proteomic Test and Comorbidity Index in Diversified Population with Lung Cancer.
    Keshtgarpour M; Tan WS; Zwanziger J; Awadalla S; Langi FG; Dudek AZ
    Anticancer Res; 2016 Apr; 36(4):1759-65. PubMed ID: 27069156
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic and predictive role of the VeriStrat plasma test in patients with advanced non-small-cell lung cancer treated with erlotinib or placebo in the NCIC Clinical Trials Group BR.21 trial.
    Carbone DP; Ding K; Roder H; Grigorieva J; Roder J; Tsao MS; Seymour L; Shepherd FA
    J Thorac Oncol; 2012 Nov; 7(11):1653-60. PubMed ID: 23059783
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the VeriStrat
    Gadgeel S; Goss G; Soria JC; Felip E; Georgoulias V; Lu S; Cobo M; Syrigos K; Lee KH; Göker E; Guclu SZ; Isla D; Morabito A; Dupuis N; Bühnemann C; Krämer N; Solca F; Ehrnrooth E; Ardizzoni A
    Lung Cancer; 2017 Jul; 109():101-108. PubMed ID: 28577938
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A retrospective analysis of VeriStrat status on outcome of a randomized phase II trial of first-line therapy with gemcitabine, erlotinib, or the combination in elderly patients (age 70 years or older) with stage IIIB/IV non-small-cell lung cancer.
    Stinchcombe TE; Roder J; Peterman AH; Grigorieva J; Lee CB; Moore DT; Socinski MA
    J Thorac Oncol; 2013 Apr; 8(4):443-51. PubMed ID: 23370367
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic role of the VeriStrat test in first line patients with non-small cell lung cancer treated with platinum-based chemotherapy.
    Grossi F; Genova C; Rijavec E; Barletta G; Biello F; Dal Bello MG; Meyer K; Roder J; Roder H; Grigorieva J
    Lung Cancer; 2018 Mar; 117():64-69. PubMed ID: 29395121
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictive value of a proteomic signature in patients with non-small-cell lung cancer treated with second-line erlotinib or chemotherapy (PROSE): a biomarker-stratified, randomised phase 3 trial.
    Gregorc V; Novello S; Lazzari C; Barni S; Aieta M; Mencoboni M; Grossi F; De Pas T; de Marinis F; Bearz A; Floriani I; Torri V; Bulotta A; Cattaneo A; Grigorieva J; Tsypin M; Roder J; Doglioni C; Levra MG; Petrelli F; Foti S; Viganò M; Bachi A; Roder H
    Lancet Oncol; 2014 Jun; 15(7):713-21. PubMed ID: 24831979
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association between serum biomarkers CEA and LDH and response in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy.
    de Jong C; Deneer VHM; Kelder JC; Ruven H; Egberts TCG; Herder GJM
    Thorac Cancer; 2020 Jul; 11(7):1790-1800. PubMed ID: 32383328
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytotoxic chemotherapy in advanced non-small cell lung cancer with poor performance status: A retrospective analysis from routine clinical practice.
    Kancharla H; Gundu N; Pathak N; Vandidassane I; Khurana S; Pushpam D; Jain D; Kumar S; Pathy S; Mohan A; Malik PS
    Curr Probl Cancer; 2020 Jun; 44(3):100550. PubMed ID: 31987521
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum proteomic test in advanced non-squamous non-small cell lung cancer treated in first line with standard chemotherapy.
    Grossi F; Rijavec E; Genova C; Barletta G; Biello F; Maggioni C; Burrafato G; Sini C; Dal Bello MG; Meyer K; Roder J; Roder H; Grigorieva J
    Br J Cancer; 2017 Jan; 116(1):36-43. PubMed ID: 27898657
    [TBL] [Abstract][Full Text] [Related]  

  • 14. VeriStrat® has a prognostic value for patients with advanced non-small cell lung cancer treated with erlotinib and bevacizumab in the first line: pooled analysis of SAKK19/05 and NTR528.
    Gautschi O; Dingemans AM; Crowe S; Peters S; Roder H; Grigorieva J; Roder J; Zappa F; Pless M; Brutsche M; Baty F; Bubendorf L; Hsu Schmitz SF; Na KJ; Carbone D; Stahel R; Smit E
    Lung Cancer; 2013 Jan; 79(1):59-64. PubMed ID: 23122759
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum albumin is a strong predictor of survival in patients with advanced-stage non-small cell lung cancer treated with erlotinib.
    Fiala O; Pesek M; Finek J; Racek J; Minarik M; Benesova L; Bortlicek Z; Sorejs O; Kucera R; Topolcan O
    Neoplasma; 2016; 63(3):471-6. PubMed ID: 26952513
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Erlotinib plus either pazopanib or placebo in patients with previously treated advanced non-small cell lung cancer: A randomized, placebo-controlled phase 2 trial with correlated serum proteomic signatures.
    Spigel DR; Burris HA; Greco FA; Shih KC; Gian VG; Lipman AJ; Daniel DB; Waterhouse DM; Finney L; Heymach JV; Hainsworth JD
    Cancer; 2018 Jun; 124(11):2355-2364. PubMed ID: 29645086
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SWOG S0709: Randomized Phase II Trial of Erlotinib versus Erlotinib Plus Carboplatin/Paclitaxel in Patients with Advanced Non-Small Cell Lung Cancer and Impaired Performance Status as Selected by a Serum Proteomics Assay.
    Lara PN; Moon J; Hesketh PJ; Redman MW; Williamson SK; Akerley WL; Hirsch FR; Mack PC; Gandara DR
    J Thorac Oncol; 2016 Mar; 11(3):420-5. PubMed ID: 26725184
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Blood serum amyloid A as potential biomarker of pembrolizumab efficacy for patients affected by advanced non-small cell lung cancer overexpressing PD-L1: results of the exploratory "FoRECATT" study.
    Di Noia V; D'Argento E; Pilotto S; Vita E; Ferrara MG; Damiano P; Ribelli M; Cannella A; Virtuoso A; Fattorossi A; Ceresoli GL; Milella M; Beretta GD; Tortora G; Bria E
    Cancer Immunol Immunother; 2021 Jun; 70(6):1583-1592. PubMed ID: 33231726
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized, placebo-controlled, multicenter, biomarker-selected, phase 2 study of apricoxib in combination with erlotinib in patients with advanced non-small-cell lung cancer.
    Gitlitz BJ; Bernstein E; Santos ES; Otterson GA; Milne G; Syto M; Burrows F; Zaknoen S
    J Thorac Oncol; 2014 Apr; 9(4):577-82. PubMed ID: 24736085
    [TBL] [Abstract][Full Text] [Related]  

  • 20. First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 trial.
    Lee SM; Khan I; Upadhyay S; Lewanski C; Falk S; Skailes G; Marshall E; Woll PJ; Hatton M; Lal R; Jones R; Toy E; Chao D; Middleton G; Bulley S; Ngai Y; Rudd R; Hackshaw A; Boshoff C
    Lancet Oncol; 2012 Nov; 13(11):1161-70. PubMed ID: 23078958
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.